BRIEF-J&J Tecvayli Plus Darzalex Faspro Combination Regimen Significantly Improves Progression-Free Survival & Overall Survival Versus Standard Of Care
Reuters
Oct 16
BRIEF-J&J Tecvayli Plus Darzalex Faspro Combination Regimen Significantly Improves Progression-Free Survival & Overall Survival Versus Standard Of Care
J&J: TECVAYLI PLUS DARZALEX FASPRO COMBINATION REGIMEN SIGNIFICANTLY IMPROVES PROGRESSION-FREE SURVIVAL & OVERALL SURVIVAL VERSUS STANDARD OF CARE
J&J: INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDED UNBLINDING PHASE 3 MAJESTEC-3 STUDY
J&J: OVERALL SAFETY PROFILE OF TECVAYLI IN COMBINATION WITH DARZALEX FASPRO CONSISTENT WITH KNOWN SAFETY PROFILES OF EACH MONOTHERAPY
Source text: [ID:]
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.